Oncology, oral solids to drive Intas's growth as it heads for IPO
This article was originally published in Scrip
Executive Summary
Intas Pharmaceuticals of India expects its oncology and oral solids businesses to drive growth as it hopes to scale the Rs20 billion ($429.8 million) turnover mark ahead of its proposed initial public offering (IPO) next year.